Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial

Jason V. Baker,1,2 Shweta Sharma,3 Birgit Grund,4 Adam Rupert,5 Julia A. Metcalf,6 Mauro Schechter,7 Paula Munderi,8 Inka Aho,9 Sean Emery,10,11 Abdel Babiker,12 Andrew Phillips,13 Jens D. Lundgren,14 James D. Neaton,3 and H. Clifford Lane6; for the INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group

Background. The Strategic Timing of AntiRetroviral Treatment (START) trial demonstrated that immediate (at CD4+ >500 cells/µL) vs deferred (to CD4+ <350 cells/µL or AIDS) antiretroviral therapy (ART) initiation reduced risk for AIDS and serious non-AIDS (SNA). We investigated associations of inflammation, coagulation, and vascular injury biomarkers with AIDS, SNA or death, and the effect of immediate ART initiation.

Methods. Biomarkers were measured from stored plasma prior to randomization and at month 8. Associations of baseline biomarkers with event risk were estimated with Cox regression, pooled across groups, adjusted for age, gender, and treatment group, and stratified by region. Mean changes over 8 months were estimated and compared between the immediate and deferred ART arms using analysis of covariance models, adjusted for levels at entry.

Results. Baseline biomarker levels were available for 4299 START participants (92%). Mean follow-up was 3.2 years. Higher levels of IL-6 and D-dimer were the only biomarkers associated with risk for AIDS, SNA or death, as well as the individual components of SNA and AIDS events (HRs ranged 1.37–1.41 per 2-fold higher level), even after adjustment for baseline CD4+ count, HIV RNA level, and other biomarkers. At month 8, biomarker levels were lower in the immediate arm by 12%–21%.

Conclusions. These data, combined with evidence from prior biomarker studies, demonstrate that IL-6 and D-dimer consistently predict clinical risk across a broad spectrum of CD4 counts for those both ART-naïve and treated. Research is needed to identify disease-modifying treatments that target inflammation beyond the effects of ART.

Keywords. coagulation; comorbidities; end-organ disease; HIV disease; inflammation risk.

Effective antiretroviral therapy (ART) has prolonged survival and shifted the morbidity spectrum for HIV+ persons away from AIDS and toward severe non-AIDS (SNA)-defining conditions, including cardiovascular disease, cancer, and other end-organ diseases [1, 2]. A key factor contributing to excess SNA event risk among HIV+ patients includes persistent abnormalities in systemic inflammation and coagulation [3–8]. Based on data from earlier large randomized trials, we and others have demonstrated that plasma measures of inflammation and/or coagulation activation predict risk for cardiovascular disease (CVD) [6, 9, 10], cancer [7], and all-cause mortality [3, 11–13], along with the composite of SNA [8, 14]. These data include patients with advanced HIV disease and/or those with low nadir CD4+ counts. It remains unclear whether ongoing inflammation is associated with clinical event risk specifically among HIV+ patients with recent diagnosis and preserved immunity (ie, CD4+ counts >500 cells/µL).

Inflammation may improve with ART, but biomarker levels continue to be abnormal among ART-treated patients with viral suppression when compared with uninfected controls [4, 15, 16]. Early HIV diagnosis and early initiation of ART is now the goal for management of HIV infection in much of the world. Importantly, prior data characterizing the effect of ART on levels of inflammatory biomarkers typically involve nonrandomized comparisons, lack of a comparison group not receiving ART, and/or participants with low CD4+ counts [15, 17–21].

The International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Timing of AntiRetroviral Treatment (START) trial randomized 4684 ART-naïve HIV+ persons with CD4+ counts >500 cells/µL to initiate ART immediately after randomization, vs deferring ART until a CD4+ count of <350 cells/µL or progression to AIDS. In START,
immediate ART initiation led to a 57% reduction in a composite outcome of AIDS and SNA nonfatal events or deaths; reductions in the risk of AIDS and SNA events were 72% and 39%, respectively [22]. START represents a global HIV+ population, and 68% of the primary end points in START occurred among participants with CD4+ counts >500 cells/µL [22]. The START trial provides a unique opportunity to study associations between biomarkers of inflammation, coagulation, and vascular injury with major clinical outcomes among patients with relative immune preservation.

METHODS

Study Design and Clinical Data Collection
The design and primary findings from the START trial have been described [22]. All participants provided written informed consent. We used specimens from study visits that occurred prior to randomization (defined as “baseline”) and at month 8, and included events that occurred through May 26, 2015, when the trial results were unblinded.

All clinical events and deaths in START were reviewed and adjudicated by an end point committee blinded to treatment assignment using pre-established criteria [22]. AIDS was defined as serious events within the 1993 expanded surveillance document of the Centers for Disease Control and Prevention, but also including Hodgkin lymphoma and excluding nonfatal Herpes simplex virus infection and esophageal candidiasis (excluded because of their lesser severity). SNA-related events consisted of any of the following conditions: cardiovascular disease (CVD; myocardial infarction, stroke, or coronary revascularization) or death from CVD; end-stage renal disease (initiation of dialysis or renal transplantation) or death from renal disease; liver disease (decompensated) or death from liver disease; non-AIDS-defining cancer (except for basal cell or squamous cell skin cancer) or death from cancer; and any other death not attributable to AIDS (see the Appendix of the primary START manuscript) [22].

Plasma Biomarkers
Using plasma collected at baseline and the month 8 visit, which was stored centrally at ~70°C, 7 plasma biomarkers were measured that reflected systemic inflammation (IL-6, high-sensitivity C-reactive protein [hsCRP] and serum amyloid A [SAA]), vascular inflammation (soluble intercellular adhesion molecule-1 [sICAM] and vascular adhesion molecule-1 [sVCAM]), immune activation (interleukin-27 [IL-27]), and coagulation activation (D-dimer). IL-6 was measured using high-sensitivity enzyme-linked immunosorbent assay (R&D Systems), D-dimer using the VIDAS system (BioMerieux), and IL-27 using immunoassay (MesoScale). A multiplex platform was used to measure hsCRP, SAA, sICAM, and sVCAM (Vascular Injury II Panel, MesoScale). All samples were analyzed by researchers blinded to treatment group.

Statistical Analyses
Biomarkers were analyzed either on the log2 scale or using rank-based methods because biomarker distributions were right-skewed, and close to normal after log transformation; also, model assumptions were usually better satisfied for log-transformed biomarkers compared with no transformation.

Associations of baseline biomarker levels (log, scale) with event risk (serious AIDS, SNA, all-cause mortality, and their composite) were estimated with Cox proportional hazards regression models, pooled across treatment groups, separately for each biomarker. We pooled the treatment groups because tests for heterogeneity showed that the associations between biomarkers and the risk of the primary outcome were similar in the immediate and the deferred ART groups for all 7 biomarkers. In addition, the homogeneity of the associations between biomarkers and clinical events was assessed across age and gender. The Cox models were adjusted for age, gender, and treatment group and stratified by region. Additional adjustment considered baseline HIV RNA level and CD4+ count given the importance for clinical risk. Biomarker associations with events were also assessed in models that contained all 7 biomarkers. The proportional hazards assumption was examined with expanded Cox models that included an interaction term for the biomarker and log failure time. Kaplan-Meier estimates of the cumulative proportion of participants with clinical events were computed in 2 ways, (1) pooled over treatment groups, by quartiles of baseline D-dimer and IL-6 levels, and (2) separately for the immediate and deferred groups, by whether the baseline biomarker level was above or below the median. In all analyses, follow-up was censored on May 26, 2015, or the date of last study contact.

Spearman’s rank correlation coefficients were computed between baseline levels of biomarkers, as well as between baseline factors (age, gender, CD4+ and CD8+ cell count, plasma HIV RNA level, body mass index [BMI], smoking status, and time since HIV diagnosis) and baseline biomarker levels.

Mean changes in biomarker levels (log, scale) from baseline to the month 8 visit were compared between the immediate and deferred ART arms by intent to treat using analysis of covariance (ANCOVA) models, adjusted for baseline biomarker levels. Mean changes were back-transformed and presented as percent change on the original biomarker scale. Similar ANCOVA models were used for subgroup analyses by CD4+ and CD8+ cell counts and HIV RNA at baseline; homogeneity of the immediate vs deferred treatment difference across subgroup variables was assessed by testing for interaction between the treatment group indicator and the subgroup variable.

Statistical analyses were performed using SAS software, version 9.3 (SAS Institute Inc., Cary NC), and R software, version 3.3 (R Foundation for Statistical Computing, Vienna, Austria). P values ≤0.05 were considered significant.
RESULTS

Participant Characteristics and Biomarker Levels at Baseline (Prior to Randomization)

The START trial enrolled 4684 HIV+ participants from 215 sites in 35 countries, and 4487 (96%) consented to store plasma. Among the 4299 (92% of START) participants with available stored plasma samples who had baseline biomarker determinations for at least 1 of the 7 biomarkers (Figure 1), the median age was 36 years; 27% were female (Table 1). Self-reported race/ethnicity reflects global enrollment from the United States (11%), South America and Mexico (24%), Europe and Israel (40%), Australia (29%), Africa (21%), and Asia (8%). The median CD4+ count and HIV viral load at entry were 651 cells/µL and 12911 copies/mL, respectively; the median time since HIV diagnosis was 1.0 year (interquartile range [IQR], 0.4–3.0 years). The mean follow-up time was 3.2 years.

Baseline biomarker levels were moderately correlated with one another (\(r \geq 0.2\); \(P < 0.0001\)) for all combinations except for any biomarkers with IL-27, and correlations of sVCAM with D-dimer and IL-6, or sICAM with D-dimer. The strongest correlations were between sICAM and sVCAM (\(r = 0.75\)), and hsCRP with SAA (\(r = 0.68\)) or IL-6 (\(r = 0.51\)). At baseline, higher levels of all 7 biomarkers were associated with higher HIV RNA level and CD8+ counts, but not lower CD4+ counts (Supplemental Figure A).

ART Use and CD4+ Cell Counts

All 4299 participants were naïve to ART at baseline (as specified by START eligibility criteria). ART was used for 94% and 29% of follow-up time in the immediate and deferred ART groups, respectively. Through all follow-up, the average CD4+ count increased in the immediate group by 173 cells/µL (95% confidence interval [CI], 164–183) and decreased in the deferred group by 20 cells/µL (95% CI, 10–29), for a difference of 193 cells/µL (95% CI, 184–203) between groups.

ART Use and CD4+ Cell Counts

Among the 3980 participants for whom baseline to month 8 biomarker changes were assessed, 1941 (98%) participants in the immediate ART group and 163 (8%) in the deferred group had initiated ART by month 8. ART had been used for 91% and 4% of time between baseline and month 8 among the immediate and deferred ART groups, respectively. By month 8, the average CD4+ cell count had increased from baseline in the immediate group by 91 cells/µL and decreased by 76 cells/µL in the deferred group. Among the immediate group participants who initiated therapy by month 8, ART included tenofovir disoproxil fumarate (TDF) for 89%, efavirenz (EFV) for 73%, a ritonavir-boosted protease inhibitor (PI) for 18%, and an integrase strand transfer inhibitor (INSTI) for 4%.

Associations of Baseline Biomarker Levels With Clinical Event Risk

Primary events (AIDS, SNA, or death) were experienced by 129 participants, 40 in the immediate and 89 in the deferred ART groups; 57 experienced fatal or nonfatal AIDS events (23 tuberculosis [TB]) and 74 SNA events or non-AIDS deaths; 50 experienced cancer (AIDS or non-AIDS; 12 Kaposi's sarcoma) and 24 CVD. Participants with, compared with without, a primary event had higher median biomarker levels at baseline (Table 1).

Figure 2 presents event risk over follow-up as predicted by baseline biomarker levels. Higher levels of D-dimer and IL-6 were associated with increased risk for the primary composite of AIDS, SNA, or death, as well as the individual components of SNA or non-AIDS death and AIDS (fatal or nonfatal). Risk for AIDS events was also associated with higher SAA and sICAM levels, and hsCRP approached significance (\(P = .053\)). D-dimer and IL-6 associations with AIDS, SNA, or death persisted after additional adjustment for baseline CD4+ count and HIV RNA level (HR, 1.36 per 2 times higher D-dimer; 95% CI, 1.11–1.66; HR, 1.35 per 2 times higher IL-6; 95% CI, 1.12–1.62). When considering models that included baseline levels of all 7 biomarkers jointly, along with age, gender, and treatment group, risk for AIDS, SNA, or death was significantly associated with IL-6 (HR, 1.34 per 2 times higher IL-6 levels; 95% CI, 1.08–1.67) and D-dimer (HR, 1.32 per 2 times higher D-dimer levels; 95% CI, 1.07–1.63), but none of the other biomarkers.

Figure 3A presents Kaplan-Meier estimates for the cumulative percentage of participants experiencing AIDS and SNA events by quartiles of the baseline levels of IL-6 or D-dimer. The associations for IL-6 and D-dimer were stronger for events that occurred more proximal to the biomarker measurements (\(P\) values for interaction with log follow-up time were 0.008 for D-dimer and 0.016 for IL-6). This change in event rates over time was more pronounced in the deferred arm for IL-6.
Associations of IL-6 and D-dimer with the risk of AIDS, SNA, or death were similar across treatment groups ($P = 0.96$ and $P = 0.97$, respectively, for interaction). This is illustrated in Figure 3B, which presents the cumulative percentage of participants experiencing the primary composite within the immediate and deferred ART groups in START, separately for those with above- or below-median IL-6 and D-dimer levels at baseline. This figure shows that the relative difference in event risk between high and low biomarker levels is similar for both the immediate and deferred groups, even though the event rate for the deferred group is higher than the event rate for the immediate group for both biomarkers. For example, in the immediate group, the cumulative event rates at month 36 were 2.2% and 0.8% for those whose baseline D-dimer was above or below the median, respectively (a ratio of 2.75); corresponding rates for the deferred group were 5.4% and 2.3% (a ratio of 2.35) (Figure 3B).

Changes in Biomarkers From Baseline to Month 8 With Immediate vs Deferred ART

In the immediate group (ART initiated at baseline), levels of IL-6, D-dimer, SAA, IL-27, sICAM, and sVCAM declined between baseline and month 8 (Figure 4). D-dimer levels increased by month 8 in the deferred ART group, and hsCRP increased in both the immediate and the deferred groups. Levels of D-dimer, IL-6, SAA, sICAM, and sVCAM declined from baseline to month 8 by 12%–21% more in the immediate group compared with the deferred group ($P < .001$ for each biomarker) (Figure 4). These differences persisted, with slightly larger magnitudes, when excluding deferred group participants who started ART prior to month 8 (data not shown). The ART-associated declines in biomarker levels at 8 months (eg, 19.1% for D-dimer and 11.6% for IL-6) are modest in absolute terms (Supplementary Table A); median D-dimer levels within the immediate

### Table 1. Baseline Characteristics in START, Overall and According to Primary Event Status ($n = 4299$)

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>Primary Eventa</th>
<th>No Primary Eventa</th>
<th>$P$ Valueb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>4299</td>
<td>129</td>
<td>4170</td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>36 [29–44]</td>
<td>44 [34–51]</td>
<td>36 [29–44]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Female gender</td>
<td>1141 (26.5)</td>
<td>27 (20.9)</td>
<td>1114 (26.7)</td>
<td>0.14</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td>0.042</td>
</tr>
<tr>
<td>Black</td>
<td>1301 (30.3)</td>
<td>41 (31.8)</td>
<td>1260 (30.2)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>1938 (45.1)</td>
<td>68 (52.7)</td>
<td>1870 (44.8)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1060 (24.7)</td>
<td>20 (15.5)</td>
<td>1040 (24.9)</td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of HIV diagnosis, y</td>
<td>1.0 [0.4–3.0]</td>
<td>1.2 [0.5–3.6]</td>
<td>1.0 [0.4–3.0]</td>
<td>0.34</td>
</tr>
<tr>
<td>CD4, cells/µL</td>
<td>651 [584–765]</td>
<td>632 [584–742]</td>
<td>651 [584–765]</td>
<td>0.26</td>
</tr>
<tr>
<td>CD4:CD8 ratio</td>
<td>0.66 [0.48–0.89]</td>
<td>0.61 [0.42–0.82]</td>
<td>0.66 [0.48–0.89]</td>
<td>0.031</td>
</tr>
<tr>
<td>HIV RNA, copies/mL</td>
<td>12 911 [3120–43 730]</td>
<td>22 726 [7485–63 956]</td>
<td>12 647 [3057–42 889]</td>
<td>0.001</td>
</tr>
<tr>
<td>Hepatitis B/C</td>
<td>276 [6.5]</td>
<td>10 (78)</td>
<td>266 (6.5)</td>
<td>0.54</td>
</tr>
<tr>
<td>Prior CVDd</td>
<td>25 (0.6)</td>
<td>3 (2.3)</td>
<td>22 (0.5)</td>
<td>0.04</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>24.5 [22.1–27.8]</td>
<td>24.6 [22.5–27.7]</td>
<td>24.5 [22.1–27.8]</td>
<td>0.66</td>
</tr>
<tr>
<td>Current smoking</td>
<td>1398 (32.5)</td>
<td>57 (44.2)</td>
<td>1341 (32.2)</td>
<td>0.004</td>
</tr>
<tr>
<td>Biomarkers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-Dimer, µg/mL</td>
<td>0.33 [0.23–0.50]</td>
<td>0.40 [0.29–0.66]</td>
<td>0.32 [0.22–0.49]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-6, pg/mL</td>
<td>1.39 [0.97–2.12]</td>
<td>1.65 [1.26–2.57]</td>
<td>1.38 [0.96–2.11]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>hsCRP, µg/mL</td>
<td>1.71 [0.74–4.01]</td>
<td>1.89 [0.93–4.54]</td>
<td>1.69 [0.73–3.97]</td>
<td>0.07</td>
</tr>
<tr>
<td>SAA, mg/L</td>
<td>4.52 [2.53–8.75]</td>
<td>5.68 [3.15–9.77]</td>
<td>4.47 [2.51–8.34]</td>
<td>0.014</td>
</tr>
<tr>
<td>sICAM, µg/mL</td>
<td>541 [423–693]</td>
<td>622 [502–751]</td>
<td>538 [422–691]</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Abbreviations: BMI = body mass index; CVD = cardiovascular disease; hsCRP = high-sensitivity C-reactive protein; IL = interleukin; IQR: interquartile range; MI = myocardial infarction; SAA = Serum Amyloid A; sICAM = soluble intercellular adhesion molecule; SNA = serious non-AIDS events, sVCAM = soluble vascular cellular adhesion.

aPrimary event refers to the composite study end point of AIDS, SNA, or death.
b$P$ value comparing those with a primary event with those without a primary event. Medians were compared using Wilcoxon rank-sum tests and proportions compared using chi-square tests. The Fisher exact test was used for comparison of prior CVD risk.
cAverage of screening and baseline values.

dMI, coronary revascularization, or stroke.
ART group were 0.32 μg/mL at baseline and 0.28 μg/mL at month 8, and corresponding values for IL-6 were 1.41 pg/mL and 1.27 pg/mL.

We carried out subgroup analyses to determine whether the immediate vs deferred treatment difference in biomarker changes was homogeneous across baseline levels of CD4+, CD8+, and HIV RNA (Supplemental Tables B, C, D). For all biomarkers, the treatment difference varied across HIV RNA levels (except for IL-27) and CD8+ count (except for SAA), and participants with higher HIV RNA levels at baseline demonstrated the greatest ART-associated declines in the immediate group and the greatest increases in the deferred group (except for IL-27) over 8 months. Specifically, among persons with HIV RNA levels ≥30,000 copies/mL at entry, D-dimer levels declined by 21% in the immediate group, but actually increased by 8% in the deferred group; corresponding changes for IL-6 levels were a 14% decline and a 12% increase, respectively.

**DISCUSSION**

In a large randomized clinical trial (START) of HIV+ patients who were early in the course of disease and had preserved immunity, we report the associations of biomarker levels of systemic inflammation, coagulation, and vascular injury with risk for clinical events, and the effect of immediate vs deferred ART initiation on these same biomarkers. Greater systemic inflammation (ie, IL-6 levels) and coagulation activity (ie, D-dimer levels) at entry in START were associated with increased risk for AIDS events, SNA events, and the composite of AIDS, SNA, or death. The detrimental effect of inflammation and/or coagulation activation was present in both the immediate and deferred ART groups in START (ie, were independent of the timing of ART initiation), and demonstrated similar associations for AIDS and SNA events when examined separately. In randomized comparisons of immediate and deferred ART initiation, immediate treatment led to significant reductions over 8 months in D-dimer, IL-6, SAA, sICAM, and sVCAM levels, both in absolute terms and relative to deferral of ART.

It is well established that HIV infection is associated with elevations in systemic inflammatory markers, cytokines, and circulating vascular adhesion molecules [4, 23, 24]. Consistent with this, we report median levels of IL-6 (1.39 pg/mL) and D-dimer (0.33 μg/mL) at entry in START that are higher than levels previously reported among populations of HIV-negative participants (1.23 pg/mL and 0.22 μg/mL, respectively, in the Multi-Ethnic Study of Atherosclerosis; median age, 60 years) [4]. In other studies, ART treatment has also been shown to decrease levels of D-dimer, IL-6, and sVCAM [15, 17, 24–26], though the degree of decrease may vary by ART regimen [17] and ART-induced viral suppression may not fully restore levels of these biomarkers to those of age-adjusted controls [4, 15, 23, 24]. Specifically, when compared with levels among uninfected individuals, IL-6 and D-dimer remain approximately 40%–75% higher among HIV+ patients on ART with viral suppression [4, 27]. We show that immediate ART initiation reduced levels of D-dimer, IL-6, SAA, sICAM, and sVCAM, even when started early in the course of HIV disease, before a clinically significant
Figure 3. Kaplan-Meier (KM) estimates for the cumulative percentage of participants experiencing AIDS, serious non-AIDS, or death in START (4299). (A) Kaplan-Meier estimates for the cumulative percentage of participants experiencing an AIDS or AIDS-death (top row) and serious non-AIDS or non-AIDS death (bottom row) pooled over study groups by quartiles of D-dimer and IL-6 at baseline (first quartile = blue; second quartile = green; third quartile = orange; fourth quartile = red). The number at risk at each year of follow-up is presented below the x-axis. (B) Kaplan-Meier estimates for the cumulative percentage of participants experiencing the composite outcome of AIDS, serious non-AIDS or death in the immediate (red lines) and deferred (blue lines) ART groups in START, separately by whether baseline level of D-dimer and IL-6 were above (solid lines) or below (dashed lines) their median at baseline.
Inflammation in START Trial • OFID • 7
decline in CD4+ count has occurred. When compared with the
effect of ART initiation (vs deferral) among a subset of partic-
ipants in the SMART trial who were not using ART at entry
(prior to initiating ART: median CD4+ count, 447 cells/mm³;
HIV RNA, 39 810 copies/mL), we report here a smaller reduc-
tion of D-dimer levels in START (31% vs 19%, respectively),
but a similar reduction for IL-6 levels (13% vs 12%, respectively,
though ART-related IL-6 changes did not reach significance in
the smaller subset of SMART) [15]. Finally, we reported a par-
adoxical increase in hsCRP levels with ART treatment, but this
lack of a decline (or an increase) has been previously described
and may be the result of improved hepatocyte synthetic function
(ie, improved hsCRP release), which was previously impaired in
the context of untreated HIV infection [15, 17, 28–31].

Our findings on clinical risk prediction add to recent literature
that has reshaped our current understanding of the mechanisms
contributing to morbidity and mortality during HIV disease in
the current era. Notably, measures of systemic inflammation are
consistently associated with risk for SNA events and the de-
velopment of individual end-organ diseases [6, 7, 32–35]. Recent
data have also suggested that the independent contribution of
CD4+ counts to CVD and other SNA event risk may be more
modest, or not apparent, at higher CD4+ counts [22, 36]. This
may explain why we did not detect a significant association with
clinical risk for IL-27, which is produced by antigen-presenting

cells and is important in T-cell immune responses. We have
previously reported that among 3766 ART-treated and virolog-
ically suppressed HIV+ patients, risk for SNA events or death
was associated with elevations in IL-6 and D-dimer (HR, 1.45
for IL-6 and 1.28 D-dimer level, per 2× higher biomarker level,
respectively) [8]. Even though the START study population
included only untreated participants with higher CD4+ counts
at entry, we estimate similar HRs for SNA event risk (HR, 1.41
for IL-6 and 1.37 for D-dimer). We also show that the adverse
effects from systemic inflammation, in terms of clinical risk
over the long term, are present for HIV+ patients whether they
start ART very early or later in their disease course (ie, both
treatment groups in START). Additional follow-up is required
in START to accurately estimate biomarker associations with
clinical event risk after viral suppression is achieved among this
population treated at higher CD4+ counts, especially given our
initial observation that biomarker associations were stronger
for early vs later events in START.

Important questions remain regarding the underlying patho-
genesis driving chronic inflammation and coagulation activity
among HIV+ patients, both before and after ART initiation.
Hypothesized mechanisms have been previously reviewed [37,
38] and may involve factors related to persistence of HIV and
related immune activation, incomplete immune recovery, loss of
regulatory function, transcription of defective proviruses [39],

Figure 4. Biomarker changes from baseline to month 8 with immediate vs deferred art initiation in START (n = 3980). The percentage change (95% CI) from baseline to
month 8 for each of the 7 biomarkers, adjusted for baseline level, is plotted for both the immediate (red circles) and deferred (blue squares) ART groups. The absolute differ-
ence between immediate and deferred groups for the percentage change from baseline to month 8 is presented below the x-axis (with P-values) for each of the biomarkers.
Abbreviations: CI = confidence interval; hsCRP = high-sensitivity C-reactive protein; IL = interleukin; sICAM = soluble intercellular adhesion molecule, sVCAM = soluble vascular cellular adhesion molecule.
reduced control of copathogens (eg, cytomegalovirus), injury to mucosal surfaces with translocation of microbial antigens, toxicity from ART, and host and lifestyle factors. We show that even among HIV+ patients who start ART very early in the course of disease, there is a subset of ART-treated patients with greater clinical risk; such patients might benefit from reducing ongoing inflammation whatever the underlying mechanisms. A central focus and priority of current HIV research is to identify anti-inflammatory strategies and determine if that will translate into reductions in clinical risk for 1 or more SNA differences in biomarker levels per-point at 8 months that precluded determination of whether immediate vs deferred ART differences in biomarker levels persisted after more prolonged viral suppression (eg, >2 years after ART initiation). Longer follow-up of START will help clarify whether the full effect of more sustained virologic suppression over years ultimately reverses the harmful effects of ART deferral (reflected in the higher levels of inflammation and coagulation biomarkers), when compared with immediate ART treatment at higher CD4+ counts. The relatively low number of events in START overall, and in the immediate ART group in particular, precluded reliable estimates of (a) event risk among any individual end-organ disease condition or focused composite, (b) event risk after viral suppression was achieved and biomarkers reached their new set points, and (c) the interaction between biomarkers and treatment group or follow-up time. Finally, participants in clinical trials may have greater adherence and health-seeking behaviors, which may impact the generalizability of results.

In START, among a global population of HIV+ persons with preserved immunity, immediate ART initiation reduced biomarker levels of systemic inflammation, coagulation, and vascular injury compared with ART deferral. Differences in biomarkers between groups were the result of reductions after ART initiation, concurrent with increases among participants who deferred ART. Associations between IL-6 and D-dimer levels and risk for AIDS, SNA, and death were present for both treatment groups in START. When combined with data from prior studies [3, 6, 8, 10, 32, 40, 41], higher levels of IL-6 and D-dimer consistently predict increased clinical risk across a broad spectrum of CD4+ counts for HIV+ patients, both ART-naive and ART-treated. Cumulatively, these observations support the need for research to better understand the mechanisms driving ongoing inflammation and coagulation abnormalities during effectively treated HIV disease, and to identify disease-modifying treatments or lifestyle interventions that reduce inflammation beyond the effects of ART.

**Supplementary Data**

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Acknowledgments**

The authors would like to specifically thank the participants in the START trial. See N Engl J Med 2015;373:795–807 for the complete list of START investigators.

**Financial support.** The START study (NCT00867048) is registered at clinicaltrials.gov. The START study is primarily funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under award numbers UM1-A0686641 and UMN1-AI120197, with additional support from the National Institutes of Health Clinical Center, National Cancer Institute, National Heart, Lung, and Blood Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (France), National Health and Medical Research Council (Australia), National Research Foundation (Denmark), Bundesministerium für Bildung und Forschung (Germany), European AIDS Treatment Network, Medical Research Council (United Kingdom), National Institute for Health Research, National Health Service (United Kingdom), and University of Minnesota.

Antiretroviral drugs were donated to the central drug repository by AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen Scientific Affairs, and Merck.

**Disclosures.** The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. A.P. received fees for speaking at 2 meetings sponsored by Gilead Sciences, for consulting for GSK Biologicals, and for attendance at an advisory board meeting from AbbVie. The remaining authors declare no relevant financial interests.

**Potential conflicts of interest.** All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**


